Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies

Joint venture aims to advance regenerative medicine developed from patient’s own cells

Last updated:
1 MIN READ
A medical staff member carries a swab sample for testing at a screening centre in Abu Dhabi.
A medical staff member carries a swab sample for testing at a screening centre in Abu Dhabi.
Reuters

Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.

In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCC’s nebuliser administration experience to develop a new treatment delivery model for PLX cells.

ADSCC has reported effective usage of nebulisers to treat patients suffering from COVID-19 infection, with stem cells sourced from the patient’s own blood.

Further discussions are also ongoing to treat chronic Graft Versus Host Disease (cGvHD) — a life-threatening immune response to the donor’s stem cells against the host (patient).

Both projects follow a recently-signed agreement between ADSCC and Pluristem to harness the power of regenerative medicine.

Sign up for the Daily Briefing

Get the latest news and updates straight to your inbox

Up Next